Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "NE-3107 Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about NE-3107 for Parkinson's disease in the seven major markets. A detailed picture of the NE-3107 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the NE-3107 for Parkinson's Disease.
The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the NE-3107 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.
Drug Summary
NE-3107 is a novel orally administered small molecule that selectively inhibits the inflammatory ERK signaling and thereby reduces neuroinflammation, inhibit inflammation-driven insulin resistance, and other major pathological inflammatory cascades.
The recently completed Phase I/II trial of NE3107 for treating Parkinson's disease depicted positive results and the company will present these results at the International Conference on Alzheimer's and Parkinson's Diseases to be held in 2023 as the data from Phase II Parkinson's Disease trial is accepted for the presentation. BioVie plans to initiate the pivotal Phase IIb trial SUNRISE-1 in 3Q2023, and SUNRISE-2 is a potentially pivotal Phase III starting late 1Q2024.
NE-3107 Analytical Perspective
In-depth NE-3107 Market Assessment
This report provides a detailed market assessment of NE-3107 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.
NE-3107 Clinical Assessment
The report provides the clinical trials information of NE-3107 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
- In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence NE-3107 dominance.
- Other emerging products for Parkinson's disease are expected to give tough market competition to NE-3107 and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of NE-3107 in Parkinson's disease.
- This in-depth analysis of the forecasted sales data of NE-3107 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the NE-3107 in Parkinson's disease.
Key Questions Answered
- What is the product type, route of administration and mechanism of action of NE-3107?
- What is the clinical trial status of the study related to NE-3107 in Parkinson's disease and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NE-3107 development?
- What are the key designations that have been granted to NE-3107 for Parkinson's disease?
- What is the forecasted market scenario of NE-3107 for Parkinson's disease?
- What are the forecasted sales of NE-3107 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
- What are the other emerging products available and how are these giving competition to NE-3107 for Parkinson's disease?
- Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?
Key Topics Covered:
1. Report Introduction
2. NE-3107 Overview in Parkinson's disease
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical studies
2.2.2. Clinical trials information
2.2.3. Safety and Efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. NE-3107 Market Assessment
5.1. Market Outlook of NE-3107 in Parkinson's disease
5.2. 7MM Analysis
5.2.1. Market Size of NE-3107 in the 7MM for Parkinson's disease
5.3. Country-wise Market Analysis
5.3.1. Market Size of NE-3107 in the United States for Parkinson's disease
5.3.2. Market Size of NE-3107 in Germany for Parkinson's disease
5.3.3. Market Size of NE-3107 in France for Parkinson's disease
5.3.4. Market Size of NE-3107 in Italy for Parkinson's disease
5.3.5. Market Size of NE-3107 in Spain for Parkinson's disease
5.3.6. Market Size of NE-3107 in the United Kingdom for Parkinson's disease
5.3.7. Market Size of NE-3107 in Japan for Parkinson's disease
6. SWOT Analysis
7. Analysts' Views
8. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/ms5wx2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
